Anbio Biotechnology Class A Ordinary Shares

NNNN | NASDAQ

$5.68

+$0.43 (+8.19%)

At close: Sep 21, 2026, 4:00 PM ET

$5.70

+$0.02 (+0.35%)

Pre-market: Sep 22, 2026, 8:58 AM ET

Fiscal Year Period Ending	FY 2025 Dec 30, 2025	FY 2024 Dec 30, 2024	FY 2023 Dec 30, 2023	FY 2022 Dec 30, 2022	FY 2021 Dec 30, 2021
Revenue	8.65M	8.19M	6.71M	23.54M	4.43M
Cost of Revenue	1.1M	2.3M	3.35M	10.98M	1.89M
Gross Profit	7.54M	5.89M	3.36M	12.56M	2.54M
Operating Income	5.77M	2M	1.96M	10.2M	2.46M
Interest Income	142.02K	337.51K	165.34K	42.25K	n/a
Pretax Income	6.4M	2.37M	2.25M	10.01M	2.54M
Net Income	6.4M	2.37M	2.25M	10.01M	2.54M
Selling & General & Admin	1.57M	3.44M	1.27M	2.17M	86.1K
Research & Development	201.31K	454.23K	134.7K	200K	n/a
Other Expenses	n/a	n/a	n/a	n/a	n/a
Operating Expenses	1.78M	3.89M	1.4M	2.37M	86.1K
Interest Expense	n/a	n/a	n/a	8K	n/a
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	2.88M	6.19M	4.75M	13.35M	1.97M
Income Tax Expense	n/a	n/a	n/a	n/a	n/a
Shares Outstanding (Basic)	43.89M	42.29M	143.89M	143.89M	100M
Shares Outstanding (Diluted)	43.89M	42.29M	187.78M	143.89M	100M
EPS (Basic)	0.16	0.06	0.02	0.07	0.03
EPS (Diluted)	0.16	0.06	0.01	0.07	0.03
EBITDA	5.77M	2.57M	2.27M	10.03M	2.54M
EBIT	5.77M	2.37M	2.25M	10.02M	2.54M
Depreciation & Amortization	n/a	n/a	13.04K	6.25K	n/a